Emergent BioSolutions Q1 Revenue Plunges 30%, Net Income Down 90% YoY Despite Beating Guidance
EBS sits 93% above its 52-week low of $4.71.
Summary
Emergent BioSolutions reported its first quarter 2026 financial results, showing significant year-over-year declines in key metrics. Total revenues fell 30% to $156.1 million, net income plummeted 90% to $6.8 million, and adjusted EBITDA decreased 55% to $35.6 million. While the company stated these results were above the high-end of their guidance range, the substantial year-over-year drops are material and likely to concern investors. This earnings report follows recent positive developments, including debt refinancing and new strategic manufacturing partnerships, but the core financial performance indicates ongoing challenges. Traders will be closely watching for further details on the company's turnaround strategy and the impact of recent initiatives on future results.
At the time of this announcement, EBS was trading at $9.11 on NYSE in the Life Sciences sector, with a market capitalization of approximately $425M. The 52-week trading range was $4.71 to $14.06. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.